Raysha Farah (@rayshafarah) header
Raysha Farah (@rayshafarah) profile picture

🩺 MD | 🧬 MMSCI @harvardmed ‘26 🎓 Harvard Dean’s Scholar 🫀 Aspiring Cardiologist Our recent JACC paper on 4 biomarkers for CAD risk: https://nitter.gq/t.co/CPfBPVRENq

Boston, MA
Joined September 2010
Raysha Farah retweeted
Celebrating the achievements of our and @mchonig ‘s teams at #AHA26 ! @MGBResearchNews @mghcvrc @broadinstitute
1
11
43
1,931
Raysha Farah retweeted
Back to back presentations at #AHA26 from our team in this excellent session moderated by @UTahirMD @rayshafarah multi-biomarker risk prediction or recurrent CAD @KelvinS_MD proteomic model for prediction of residual CAD despite low clinical and genetic risk @MGBResearchNews @MGHHeartHealth @mghcvrc @broadinstitute
1
5
10
608
Raysha Farah retweeted
The P4 trial published today in @NEJM and #TCT2026 will shepherd a new era of PCI with CT guidance Coronary CT Angiography guided PCI was noninferior to IVUS-guided PCI with respect to target-vessel failure at 12 months Congrats to @ColletCarlos and the PCI navigator team at @Heartflow nejm.org/doi/full/10.1056/NE…
2
5
13
928
Excited to have one day, two posts on coronary artery diseases😄 🫀Our research on genomics of CAD was published in @NatureComms: An integrated germline and somatic genomic model for coronary artery disease As genomic medicine moves closer to routine clinical use, mixed signals from different genetic tests risk confusing patients and clinicians alike. Our goal was to consolidate all available genomic information into a single, interpretable risk estimate, much like how clinical risk calculators integrate blood pressure, cholesterol, and diabetes into one clinically actionable estimate. We developed an integrated genomic model (IGM) that combines six germline and somatic genetic drivers of coronary artery disease (CAD) into a single risk estimate derived from one DNA sample. Key takeaways: 1️⃣ With integrated genomic model, we identified about 13% of CAD high-risk individuals who would have been missed by polygenic risk score alone. These are people whose risk stems from combinations of familial hypercholesterolemia variants, clonal hematopoiesis, or shortened telomere length. 2️⃣ The IGM captures individuals at high risk who lack any single obvious high-risk genetic factor. Their elevated risk comes from the accumulation of multiple moderate genetic signals across different biological pathways. Conversely, some individuals carrying known high-risk variants (like FH variants) are protected by favorable profiles elsewhere in their genome. 3️⃣When combined with the clinical risk scores (PCE, the guideline-recommended clinical calculator), the IGM provided the strongest risk stratification, reclassifying individuals across every clinical risk category. This work would not have been possible without the @broadinstitute, @MGBResearchNews, @MassGenBrigham , and the @CAS__Science. I am grateful to have co-led this project with Xiong Yang, guided by the exceptional mentorship of @pnatarajanmd, @MinxianWang, and @aklfahed. Special thanks to @hongheeW, @patrick_ellinor, @NakaoTetsushi, @somijemmacho, @skoyamamd (to mention few), and the entire NHLBI TOPMed Consortium for their contributions.
🫀Excited to share research that I supervised as senior author, now published in @NatureMedicine: the largest global analysis of ischemic heart disease burden attributable to suboptimal diet to date. As a researcher in cardiovascular epidemiology, I've always believed that what we eat is one of the most powerful levers we have for preventing heart disease. Our data now quantify just how large that lever is, and the findings are both sobering and actionable. We assessed 13 dietary risk factors across 204 countries from 1990 to 2023. In 2023 alone, suboptimal diet was responsible for an estimated 4.06 million ischemic heart disease deaths worldwide. Key takeaways: 1️⃣ The patterns of suboptimal diet vary substantially across the globe. While developing countries most often face ischemic heart disease burden related to undernutrition and limited access to protective foods (ie, whole grains, fruits, vegetables, omega-3 fatty acids), developed countries are more commonly burdened by overconsumption of harmful dietary components (ie, processed meats, sugar-sweetened beverages). 2️⃣Global efforts have historically targeted sodium, sugar, and fat reduction. Our data suggest that promoting the intake of whole grains, nuts, fruits, and legumes deserves equal, if not greater, priority. Special thanks to the @IHME_UW for enabling this work and to the remarkable #GBD collaborators worldwide. It has been a privilege to supervise and work closely with Sooji Lee, Hayeon Lee, Yejun Son, Jae Il Shin, alongside Prof. Dong Keon Yon. Paper: nature.com/articles/s41591-0… #CardiovascularHealth #Diet #Nutrition #IHD #CAD #GBD #GlobalHealth #PublicHealth #HeartDisease #FoodIsMedicine @broadinstitute | @MGBResearchNews | @MassGenBrigham | @kh_univ
4
15
1
48
10,379
Raysha Farah retweeted
New from our group published in @NatureComms nature.com/articles/s41467-0… What is the maximal information you can get from a single DNA sample to predict heart attack risk? We developed an integrated genomic model that combines germline (polygenic risk scores, monogenic variants) and somatic (CHIP, LTL) information. Risk is demonstrated as a gradient on a 2D envelope capturing germline and somatic risk. We identify ~ 13% of high-risk individuals who would have been missed by polygenic risk score alone. Wonderful collaboration co-led with @pnatarajanmd and @wallacemwang Thread form postdoc extraordinaire and co-first author @MinSeoKim_MD in comments @MGBResearchNews @broadinstitute
2
4
22
1,257
Raysha Farah retweeted
Validation of aggressive LDL lowering to reduce major adverse cardiovascular events, a randomized trial targeting LDL < 55 mg/dl. In participants with atherosclerotic cardiovascular disease (secondary prevention) @NEJM #ACC26 nejm.org/doi/full/10.1056/NE…
21
77
4
386
42,081
Raysha Farah retweeted
HARP study is out at #ACC26 with simultaneous publication @CircAHA OCT + Cardiac MRI identified diagnosis in 79% or MINOCA patients Some examples from our participants below — intraplaque hemorrhage and plaque rupture that would otherwise be missed on coronary angiography Congrats to Harmony Reynolds who led this effort over several years
#SimPub #ACC26 OCT + cardiac MRI identified a diagnosis in 79% of MINOCA patients: true MI in 59%, mimic in 20%. Clinical factors poorly predicted imaging findings, emphasizing ... @BaineyKevin @SripalBangalore @yadersandoval @aklfahed @HashimHayder ahajrnls.org/4uXCV3J
1
2
11
1,868
A combination of 4 biomarkers 👉polygenic risk score 👉LDL-C 👉Lp(a) 👉hsCRP shows high predictive performance for incidence of coronary artery disease, especially in younger individuals.
4
16
47
2,415
Raysha Farah retweeted
Deep dive from @TCTMD_Caitlin about our recent paper and the concept of biomarker measurement to predict future cardiovascular disease, inform mechanisms that could be targeted, and potentially prioritize people for imaging. Appreciate the insights also from @SumeetKhetarpal
Genomics, Lipids, Inflammation at Midlife Predict Future CAD dlvr.it/TRhqq9
1
4
759
Raysha Farah retweeted
Wonderful editorial from @iftikhar_kullo about our recent paper in @JACCJournals From Risk Factors to Pathways: A New Framework for Coronary Heart Disease Prevention "“Reducing the burden of CHD requires moving beyond risk prediction approaches developed more than 6 decades ago toward contemporary methods that leverage our understanding of disease biology.” jacc.org/doi/10.1016/j.jacc.…
3
21
1,281
Raysha Farah retweeted
A one-time midlife assessment of four blood-based biomarkers—CAD polygenic risk score (PRS), hsCRP, LDL-C, and lipoprotein(a)—robustly predicts future coronary artery disease risk in both men and women aged 40 to 69 years. A one-time midlife biomarker panel may unmask hidden future CAD risk long before conventional calculators do. 🔹 Pearl 1 — Four pathways, one practical panel A single midlife assessment of CAD polygenic risk score (PRS), LDL-C, lipoprotein(a), and hsCRP captures genetic, lipid, and inflammatory risk, offering a more integrated view of future coronary artery disease risk. 🔹 Pearl 2 — Each biomarker independently predicts incident CAD Over 12 years of follow-up, elevation of each biomarker was independently associated with higher CAD risk. The hazard ratios were 1.79 for CAD PRS, 1.60 for LDL-C, 1.20 for Lp(a), and 1.64 for hsCRP, confirming that all four add meaningful prognostic information. 🔹 Pearl 3 — Risk is multiplicative, not merely additive Individuals with all four biomarkers elevated had a 4.65-fold higher risk of future CAD compared with those with no elevated biomarkers, highlighting the importance of cumulative burden across pathways. 🔹 Pearl 4 — Younger adults may benefit the most All four biomarkers showed stronger associations at younger ages, suggesting that biomarker-based screening may be especially valuable in early midlife, when traditional clinical calculators often underestimate lifetime vascular risk. 🔹 Pearl 5 — Biomarkers can rival traditional risk calculators The combined 4-biomarker model achieved a C-statistic of 0.753, which was slightly better than the pooled cohort equations at 0.740, indicating comparable or better discriminatory performance. 🔹 Pearl 6 — Better reclassification means fewer missed patients Compared with pooled cohort equations, the 4-biomarker strategy produced a 32% continuous net reclassification improvement, suggesting it may identify at-risk individuals who would otherwise be missed by conventional clinical scoring. 🔹 Pearl 7 — CAD PRS appears particularly informative in men The association of CAD PRS with incident CAD was stronger in men than in women, although the 4-biomarker model was predictive in both sexes. 🔹 Pearl 8 — Lp(a) still matters even when effect size is modest Although the hazard ratio for Lp(a) was lower than for the other markers, it remained an independent predictor of CAD, reinforcing the value of at least once-in-a-lifetime Lp(a) testing in risk stratification. 🔹 Pearl 9 — hsCRP keeps inflammation in the CAD conversation The strong association of hsCRP with future CAD supports the concept that residual inflammatory risk deserves attention alongside cholesterol and inherited risk. 🔹 Pearl 10 — Think beyond 10-year risk; think lifetime vascular exposure This study supports interpreting CAD risk as a cumulative lifetime burden of inherited susceptibility, atherogenic lipids, and inflammation, which may help clinicians prioritize earlier and more targeted primary prevention. Practical CME INDIA Take-Home Message In adults aged 40–69 years, a one-time 4-marker panel of CAD PRS, LDL-C, Lp(a), and hsCRP may refine CAD risk assessment beyond traditional calculators, especially in younger individuals and those who appear low-risk by routine clinical scoring. This approach may help clinicians identify candidates for earlier lifestyle intensification, lipid lowering, closer follow-up, and personalized prevention strategies. One-Line Conclusion Midlife CAD prevention may become smarter when we measure inherited risk, cholesterol burden, lipoprotein(a), and inflammation together—not separately. sciencedirect.com/science/ar…
17
53
3,229
Combining Genomics With #Lipid and Inflammatory Biomarkers to Predict #CAD Risk: UK Biobank Study | JACC jacc.org/doi/10.1016/j.jacc.…
1
7
23
1,328
Raysha Farah retweeted
The 4 biomarkers to meaningfully assess a person's risk of coronary artery disease @rayshafarah @aklfahed @pnatarajanmd @JACCJournals @uk_biobank sciencedirect.com/science/ar…
14
194
5
620
51,612
Raysha Farah retweeted
New from @rayshafarah in our group published in @JACCJournals 🔸 A single measurement of 4 blood-based biomarkers in midlife, namely CAD PRS, hsCRP, LDL-C, and Lp(a), is strongly predictive of future CAD incidence in both sexes and across the age spectrum from 40 to 69 years 🔸 A biomarker-based prediction model achieves comparable performance with clinical risk calculators and may identify populations who are not detected using a traditional clinical risk calculator, creating an opportunity for improved primary prevention, particularly in younger age groups, where the performance of biomarker-based screening is highest. 🔸 Interpreting risk as a cumulative burden of genetic, lipid, and inflammatory pathways provides a straightforward approach to prioritizing earlier, targeted primary prevention. Article: authors.elsevier.com/a/1mnoA… Builds on prior work form Paul Ridker et al in @NEJM last year nejm.org/doi/full/10.1056/NE… going from 3 to 4 biomarkers by adding genetics @MinSeoKim_MD @buutruong11 @YangSui @somijemmacho @AniruddhPatelMD @pnatarajanmd @MGBResearchNews @broadinstitute
2
31
81
6,829
Raysha Farah retweeted
A single measurement of four biomarkers (CAD PRS, LDL-C, Lp(a), and hs-CRP) in middle age improves ASCVD risk prediction Presented by @harvardmed student in the lab @rayshafarah #AHA25 ahajournals.org/doi/abs/10.1…
3
10
609